CHICAGO - Investigators are reporting favorable results in a phase I pharmacokinetic and biodistribution study in men with bone metastases resulting from castration-resistant prostate cancer (CRPC) who received escalating doses of radium-223. The findings were released at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO). Jorge A. Carrasquillo, MD, with Memorial Sloan-Kettering Cancer Center in New York City, and colleagues assessed the dose-limiting toxicity (DLT) of radium-223 in ten patients during the first four weeks after treatment…

Here is the original post: 
Radium-223 Shows Early Promise In Prostate Cancer Patients With Bone Metastases

You may also like:

• Brookdale University Hospital And Medical Center Receives HANYS’ 2010 Community Health Improvement Award
• HDMA Recognizes Congressman Mike Ross (D-Ark.) With Rx Safety And Healthcare Leadership Award
• $3 Million In Medical Research Grants To Support Projects Targeting Brain Injuries, Pain Management, And Innovations In Healthcare Delivery Systems
• Scientists Genetically Transform Yellow Fever Vaccine To Fight Malaria
• Nab-Paclitaxel/Bevacizumab Combo Shows Potential In Triple-Negative Breast Cancer
• Nationwide Children’s Hospital Opens New MRI Suite Featuring A One-of-a-Kind Layout
• Mexican Americans Less Likely Than Whites To Call 9-1-1 For Stroke
• Bedbugs, Scabies And Head Lice Oh My!
• Obama’s FY 2011 Budget Gives Global Health Funding Boost
• Pneumococcal Conjugate Vaccines Effective At Preventing Child Deaths